News

With the upcoming entry into force of the "Cannabis as Medicine" law, a cannabis agency has been established at the BfArM. The cannabis agency will control and regulate the cultivation of cannabis for medical purposes in Germany. Immediately after its establishment, the cannabis agency will start an EU-wide tendering procedure and subsequently award contracts for cultivation to suitable companies. The...

At the conference "Next Generation Pharmacovigilance", held on 18 May 2016 in Zagreb, Agency for Medicinal Products and Medical Devices (HALMED) presented the mobile application for the reporting of suspected adverse drug reactions (ADR reporting). HALMED is among the first three European medicinal product agencies that introduced applications for ADR reporting via smartphones. The mobile application is meant for patients,...

Agency for Medicinal Products and Medical Devices of Croatia (HALMED) had successfully fulfilled all conditions within the evaluation conducted by the Canadian regulatory body Health Canada with the purpose of implementation of the Mutual Recognition Agreement with Canada (EC-Canada MRA) in the area of conformity of good manufacturing practice (GMP) programs. The operational phase of the agreement begins on 1...

Agency for Medicinal Products and Medical Devices of Croatia HALMED) has been officially confirmed as a member of international organisation Pharmaceutical Inspection and Co-operation Scheme (PIC/S). HALMED's membership had been approved by the PIC/S Secretariat in October 2015 and will formally begin on 1 January 2016. This important achievement confirmed once again the exceptional competence of HALMED's employees who enabled HALMED's...

Legal basis in HR The sunset clause is applied under the provision of the Article 54 of the Medicinal Products Act (Official Gazette, No. 76/13 and 90/14) in HR.  According to this Act, if a medicinal product has not been placed on the market in the Republic of Croatia for three years since the date of the granting of a marketing...

The EDQM has organised a Webinar for January 17th on elemental impurities to assess the impact of the implementation of ICH guideline Q3D, which is applicable for new marketing authorisations since June 2016, on the texts of the European Pharmacopoeia and on the assessment of CEP applications.  More info available here. The eCTD specifications of EU Module 1 changed to version...

The 10th Italian National Meeting of Qualified Persons, promoted by a trade association, took place in Rome on the 25th November, 2016. One of the topics discussed during the meeting was the data integrity.  The Italian Medicine Agency (AIFA) defined this as a key element within their inspections.  In fact, many Italian manufacturing sites are also authorised by the US FDA...

This quarter marks the breakthrough of data-integrity as a new, important element of GMP-systems worldwide. While the MHRA already issued its Guidance for Industry in March 2015, in April 2016 the FDA issued a similar guideline. So we will have to prepare ourselves for this theme to arrive on the table during GMP-audits. For that reason, we will have to...

Jan 2016 – CESP submission is accepted for HU in the case of new marketing authorisation applications for human medicinal products (in either eCTD or NeeS) for MRP/DCP and national applications only. Jan 2016 – eAF is mandatory in case of registration, variation and renewal.  In addition a paper copy is still required if eAF does not contain e-signature 13 June 2016...